Business context and reporting period
Quince Therapeutics, Inc. filed this Form 8-K on October 6, 2026, reporting results of a special stockholder meeting held that day. The filing reports corporate approvals and share authorization changes, not operating or quarterly financial results.
Financial and capital metrics
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or financial guidance figures.
- As of the meeting record date, 1,017,063 common shares were outstanding. Holders of 611,465 shares—about 60%—were present or represented by proxy.
- Stockholders approved increasing authorized common shares from 250,000,000 to 275,000,000. The amendment became effective October 6, 2026.
Material changes and approvals
- Stockholders approved the 2026 Equity Incentive Plan. Its initial reserve is 821,872 shares, plus up to 1,377,845 shares from certain unissued, forfeited, withheld, or otherwise returned awards under prior plans. Beginning January 1, 2027, the reserve automatically increases annually through 2036 by 5% of the specified year-end share count, unless the Board sets a lower amount.
- Stockholders approved the 2026 Employee Stock Purchase Plan (ESPP), with an initial reserve of 142,045 shares. Beginning January 1, 2027, its reserve automatically increases annually through 2036 by the lesser of 1% of the specified year-end share count or twice the initial reserve; the Board may set a lower increase.
- Stockholders approved issuance of shares upon conversion of Series C Non-Voting Convertible Preferred Stock and exercise of related warrants, as well as options to purchase Orphai Therapeutics, LLC common stock. The filing says the issuance will represent more than 20% of outstanding common shares and may, together with management and Board changes, result in a change of control.
- Stockholders also approved the private-placement share issuances upon conversion of Series C Preferred Stock and exercise of related warrants under Nasdaq Listing Rule 5635(d).
Vote results and other notable items
| Proposal | For | Against | Result |
|---|---|---|---|
| Issuances tied to Series C securities and Orphai options | 180,550 | 5,742 | Approved |
| Private-placement issuances under Nasdaq Rule 5635(d) | 343,517 | 5,759 | Approved |
| Increase authorized common shares | 599,460 | 11,184 | Approved |
| 2026 Equity Incentive Plan | 298,960 | 50,399 | Approved |
| 2026 ESPP | 303,437 | 45,864 | Approved |
The adjournment proposal was not presented because sufficient votes had been obtained for Proposals 1, 2, and 3. For Proposal 1, 162,971 shares were excluded from votes in favor in accordance with Nasdaq rules.
Investor points to verify
- Review the detailed terms of the Series C securities, warrants, and Orphai options, including potential share issuance and resulting ownership or control effects.
- Assess potential dilution from the authorized-share increase and the equity plan and ESPP reserves, including their automatic annual increases.
- Consult the filed plan documents and certificate amendment for governing terms; the 8-K summaries are qualified by those documents.